In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning

Colon cancer is one of the most common cancers and one of the main causes of death worldwide. Therefore, new treatment methods with better efficiency and fewer risks are very necessary. Mebendazole (MBZ), a drug commonly used for helminthic infections, has recently received attention as a suitable candidate for the treatment of various cancers. This study aimed to investigate, in vitro and in vivo, anticancer activity and selectivity Index of MBZ on colon cancer. HT-29 (human colorectal adenocarcinoma) and MCF-10 (non-tumorigenic epithelial) cell lines were treated with MBZ and Doxorubicin (DOX; positive control drug). IC50 values were estimated using methyl thiazole diphenyl-tetrazolium bromide (MTT) assay. We employed flow cytometry using annexin V-FITC and propidium iodide dyes. For the animal study, colon cancer was subcutaneously induced by CT26 cells (mouse colon cancer) in Bulb/C mice. The mice were treated with 0.05 of LD50, intraperitoneal, every other day for 35 days. Finally, the survival rate, tumor volume, and tumor weight were calculated. Our results demonstrated that IC50 values after 72 h for HT29 and MCF-10 cell lines were 0.29 +/- 0.04 mu M and 0.80 +/- 0.02 mu M, respectively. MBZ was more selective than DOX in inhibiting the proliferation of cancer cells compared to normal cells (2. 75 vs. 2.45). Annexin V/PI staining demonstrated that MBZ treatment at IC50 concentrations induced (78 +/- 12%) apoptosis in the HT29 cancer cell line after 48 h (P <= 0.0001). Also, in mice bearing colon cancer, MBZ significantly reduced the tumor volume (1177 +/- 1109 mm3; P <= 0.001) and tumor weight (2.30 +/- 1.97 g; P <= 0.0001) compared to the negative control group (weight 12.45 +/- 2.0 g; volume 7346 +/- 1077). Also, MBZ increases mean survival time (MST) and increase life span (ILS) percentage in the animal study (51.2 +/- 37% vs 93%, respectively). This study suggests that mebendazole strongly and selectively inhibits proliferation and induces apoptosis in colon cancer cells. It may be, accordingly, a promising drug for clinical research and application.

Automated summary

Mebendazole (MBZ) has shown promising anticancer activity and selectivity against colon cancer cells. In vitro and in vivo studies demonstrated that MBZ effectively inhibited cell proliferation and induced apoptosis in colon cancer cells, while having minimal impact on normal cells. Additionally, MBZ significantly reduced tumor growth and increased lifespan in mice with colon cancer.